Attainment of the lighter stage of general anesthesia is practiced widely on intensive care patients to enable patients to tolerate invasive diagnostic and therapeutic (e.g., mechanical ventilation *via* an endotracheal tube) maneuvers. These general anesthetics go on for days, if not weeks, with escalating doses exposing the patient to cumulative benefits as well as to toxicities that are not encountered in the few hours of anesthesia typical for surgical patients in the operating room. The intensive care unit (ICU) is the most expensive clinical environment by far, consuming nearly 10% of all health care dollars in the USA -- *nearly 1% of the total GDP*! The focus of attempts to curtail those costs has been on preventing complications in order to reduce the ICU length of stay. Intensivists have led this assault through widespread adoption of guidelines that have resulted in decreases in catheter-associated bloodstream infections, ventilator-associated pneumonias, and stress-induced ulcers. They have launched ambitious strategies to combat the ravages of sepsis with limited success. However, little has been done to reduce the incidence and prevalence of delirium, and the interplay between sleep and sedative-hypnotics in the genesis of this condition has not been explored. We first present a review of the restorative properties of sleep, particularly on cognitive function, the clinical evidence for sleep disruption and cognitive dysfunction in ICU patients, and how existing sedative-hypnotic agents may exacerbate or ameliorate this situation. We performed a wide-ranging MEDLINE search for relevant articles with keywords including "sleep", "sedation", "hypnotic", "delirium", "cognitive dysfunction," and "memory".

Sleep and restoration of cognitive function {#Sec1}
===========================================

Sleep is under control of two processes, a circadian clock that regulates the appropriate timing of sleep and wakefulness across the 24-hr day and a homeostatic process ("sleep homeostasis") that regulates sleep need and intensity according to the time spent awake or asleep.[@CR1] Sleep is a non-homogenous state that can be divided into non-rapid eye movement (NREM) sleep and rapid eye movement (REM; "paradoxical") sleep. Neurochemical changes accompany these different types of sleep, with cholinergic (in brain stem and forebrain), noradrenergic (locus ceruleus), and serotonergic (dorsal raphe) activity all becoming less active in NREM sleep and cholinergic activity increasing in REM sleep[@CR2] (Fig. [1](#Fig1){ref-type="fig"}a). Activity in the ventrolateral pre-optic nucleus (VLPO) is increased in NREM sleep, and the γ-aminobutyric acid (GABA)ergic/galanin input from VLPO inhibits the histaminergic tuberomammillary nucleus[@CR3] (Fig. [1](#Fig1){ref-type="fig"}a). Orexinergic pathways from the perifornical nucleus are inactive during NREM sleep (Fig. [1](#Fig1){ref-type="fig"}a).[@CR3] Fig. 1Neural mechanisms of γ-aminobutyric acid (GABA)ergic and α~2~ adrenoceptor agonist sedation. **a** Wakefulness is promoted by the release of the arousal-promoting monoamine (red) neurotransmitters, norepinephrine (NE), serotonin (5-HT), and histamine (His), from the locus ceruleus (LC), dorsal raphe nucleus (DR), and tuberomammillary nucleus (TMN), respectively, as well as acetylcholine (ACh; orange) from the pedunculopontine and laterodorsal tegmental nuclei (PPTg and LDTg) and orexin (OX; green) into the cortex, forebrain, and subcortical areas. Conversely, during the deeper stages of NREM sleep, the activity is reversed by the inhibitory action of GABA and galanin (gal; purple) released from the ventrolateral pre-optic nucleus (VLPO). **b**, **c** Activity in brain nuclei involved in sleep pathways under sedation with a (b) GABAergic agent and **c** α~2~ adrenoceptor agonist. Abbreviations: GABA gal = neurons containing GABA and galanin; His = histamine; NA = noradrenergic; ORX = orexin; LC = locus ceruleus; PeF = perifornical nucleus; TMN = tuberomammillary nucleus; VLPO = ventrolateral pre-optic nucleus. Reproduced with permission from Nelson *et al.* (**a**)[@CR27] and modified with permission (intensetimes issue 9; available at [www.intensetimes.eu](http://www.intensetimes.eu)) from Sanders *et al*. (**b**, **c**)[1](#Fn1){ref-type="fn"}

Applying electroencephalogram (EEG) criteria, NREM sleep is composed of four distinct stages. Stages 1 and 2 reflect light sleep and are followed by stages 3 and 4 of a deep sleep plane. Stages 3 and 4 are often paired together as slow-wave sleep (SWS), as the EEG in these stages is dominated by a delta rhythm (frequency 0.5-4 Hz). Slow-wave sleep may be the mechanism that drives sleep homeostasis, as it peaks early on during sleep and decreases with the decline in sleep pressure.[@CR1] Physiologic repair of the organism is accelerated during SWS, as evidenced by the increase in the rate of anabolism.[@CR4] Within the brain, the slow wave activity (the "power" in the delta rhythm range) diminishes strengthening of synapses that have occurred during wakefulness[@CR5],[@CR6] and restores the brain to a state that is subsequently capable of appropriately processing new sensory input in the succeeding period of wakefulness.[@CR7] These synaptic homeostatic processes[@CR6] accommodate the brain's energy[@CR8] and space[@CR9] requirements and allow the brain to acquire new information, which would not be possible in the absence of downscaling synaptic strength.

The different forms of memory, referred to as declarative or explicit (consciously accessible memories of fact-based information -- knowing "what") and non-declarative or implicit (procedural memory -- knowing "how") develop over time through several unique stages (acquisition, translocation, consolidation \[comprising stabilization and enhancement\], and reconsolidation). Deeper stages of NREM as well as REM sleep are required for some of these stages of learning and memory.[@CR2],[@CR10]-[@CR12] Truncating stages of sleep can result in development of cognitive dysfunction,[@CR2],[@CR13] the most severe of which occurs following total sleep deprivation.[@CR10]

We consider that impairment in the formation and retrieval of memories may account for much of the cognitive dysfunction associated with delirium. It seems intuitive that memory deficits combined with a fluctuating level of arousal (both symptoms of sleep deprivation) could produce a disorientated patient with reduced attention (Box) -- a description of the delirious patient. Nonetheless, sedative medication also directly affects memory (independently from effects on sleep), and this likely also contributes to the delirium phenotype.Box Delirium is defined by the presence of disturbed consciousness (reduced clarity of awareness of the environment with reduced ability to focus, to sustain, or to shift attention) and a change in cognition (such as memory deficit, disorientation, or language disturbance) or the development of a perceptual disturbance that is not better accounted for by a pre-existing, established or evolving dementia. The disturbance develops acutely (usually hours to days) and tends to fluctuate during the course of the day. Delirium may exhibit hyperactive or hypoactive features. Key risk factors for delirium include age, co-morbidity, an acute inflammatory precipitant, sleep deprivation and sedative medication that targets γ-aminobutyric acid (GABA)~A~ receptors.Reference: American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders,* 4th ed. Washington, DC: APA, 1994

Sleep disruption and cognitive dysfunction in ICU patients {#Sec2}
==========================================================

Early polysomnographic studies had revealed extreme sleep disruption in ICU patients, with decreases in total sleep time, altered sleep architecture (predominance of stages 1 and 2 sleep, decreased or absent stages 3 and 4 and REM sleep, and shortened REM periods), sleep fragmentation,[@CR14],[@CR15] and up to 50% of total sleep time occurring during the light phase. Among the causes contributing to sleep disruption in the ICU are those related to the patient's acute illness and co-morbidities, environmental factors (including noise and inappropriate light), and iatrogenic factors, including frequent care-related interruptions and medications prescribed for analgesia and sedation. Among the causes potentially amenable to modification, excessive noise appears not to contribute as much as was anticipated,[@CR16] and attention has focused on sedative practices.[@CR17],[@CR18] Several studies have now demonstrated the association between benzodiazepine use and both greater incidence[@CR19] and duration[@CR20] of delirium in medical ICU patients, although the relationship of the development and duration of delirium to sleep disruption was not ascertained. Acute withdrawal from long-term sedation with benzodiazepines and opiate narcotics results in profound sleep disruption.[@CR21] Interestingly, although the α~2~ agonists can be used to treat symptoms of acute withdrawal from psychoactive drugs, the effect they have on withdrawal-induced sleep disturbances has not been reported.

Mechanisms and use of sedative-hypnotic agents in the ICU {#Sec3}
=========================================================

Benzodiazepines enhance fast inhibitory neurotransmission by modulating the activity of GABA~A~ receptors in postsynaptic membranes. The GABA~A~ receptor is a heteropentamer, and most GABA~A~ receptors have a binding site for benzodiazepines (formed by α and γ~2~ subunits) in addition to binding sites for the physiological neurotransmitter GABA (formed by α and ß subunits).[@CR22] Knock-in studies perturbing the GABA~A~ receptors in mice have revealed that the α~1~ subunit in glutamatergic forebrain neurons is necessary for changes in locomotion (sedation), while the α~2~ subunit in hypothalamic nuclei is required for the transduction of the hypnotic properties (and its attendant EEG properties) of benzodiazepines.[@CR23],[@CR24] Benzodiazepine hypnotics depress slow-wave activity in NREM sleep, not only during the night when subjects receive the drugs but also during the subsequent night.[@CR25] Neither sleep homeostasis nor circadian rhythm is altered by acute benzodiazepine administration. Recently, the dopaminergic action of benzodiazepines has been revealed, which is mediated through the α~1~ subunit containing GABA~A~ receptors in the reward centre (nucleus accumbens). The GABA~A~ receptors likely contribute to the addictive features of benzodiazepines.[@CR26]

In a series of studies involving GABAergic agents, we reported that, unlike NREM sleep, these hypnotic agents did not alter noradrenergic activity in the locus ceruleus (Fig. [1](#Fig1){ref-type="fig"}b).[@CR27],[@CR28] Instead, these agents converged on the NREM sleep pathway at the level of the hypothalamus.[@CR28] Nonetheless, short-term administration of the GABAergic agent, propofol, permits normal recovery after a period of sleep deprivation, indicating similarities between propofol-induced hypnosis and sleep.[@CR29]

Benzodiazepines also exert significant memory-modulating effects, though the extent to which they impair explicit and implicit memory appears paradigm dependent.[@CR30] While some have suggested that both implicit and explicit memory are impaired following administration of midazolam,[@CR31] only explicit memory is affected in children.[@CR32]

We have shown that α~2~ agonists transduce their hypnotic response after binding to the α~2A~ receptor subtype[@CR33] through effects in the locus ceruleus (LC).[@CR34],[@CR35] The noradrenergic neurons become hyperpolarized and are less likely to achieve an action potential due to signalling processes that involve both pertussis toxin-sensitive G proteins[@CR36] and effector mechanisms, including inhibition of adenylyl cyclase[@CR34] and ligand-gated calcium channels as well as activation of inwardly-rectifying potassium channels.[@CR37]

The relatively quiescent LC facilitates a series of changes, including activation of the galanin/GABA-containing neurons of the VLPO nucleus that terminate on and inhibit aminergic neurons within the tuberomammillary nucleus (Fig. [1](#Fig1){ref-type="fig"}c).[@CR38] Thus, α~2~ agonists are associated with similar changes in neuronal activity as is seen in NREM sleep,[@CR3],[@CR39] apart from the absence of an inhibitory effect on the orexinergic neurons in the perifornical nucleus.[@CR28] In a functional magnetic resonance imaging (fMRI) study comparing sedation with α~2~ agonists and benzodiazepines, we showed that a thalamic nucleus receiving afferent input from orexinergic neurons is activated during an arousal stimulus in α~2~ agonist-sedated subjects but not in benzodiazepine-sedated subjects.[@CR40] The preservation of orexin signalling may account for the patient rousability noted with dexmedetomidine sedation. In turn, this clinical effect may be important in permitting weaning from mechanical ventilation and patient examination.

Compatible with overlapping neural substrates, dexmedetomidine induces a very similar EEG pattern in human volunteers as that seen in stages 2-4 of NREM sleep.[@CR41] Children sedated with dexmedetomidine exhibited an EEG pattern that was similar to that seen in stage 2 NREM sleep.[@CR42] Dexmedetomidine and sleep also share similarities in hypercarbic ventilator,[@CR43] hormonal,[@CR44] and auditory evoked response.[@CR45]

Recently, Veselis *et al.* addressed the effects of dexmedetomidine in a particular memory paradigm (continuous recognition task) and reported less memory perturbation (if any) than was seen with GABAergic agents.[@CR46] In animal studies, acutely-administered dexmedetomidine was noted to have variable effects on learning and memory depending on the dose.[@CR47] Recently reported rat studies showed that dexmedetomidine interferred only with memory formation if perception of sensory input was decreased during very deep levels.[@CR48]

Relevant clinical investigations {#Sec4}
================================

Two randomized controlled trials (RCTs) investigated whether dexmedetomidine could provide superior sedation to benzodiazepine sedation. The Maximizing Efficacy of Targeted Sedation and Reducing Neurological Dysfunction (MENDS) RCT compared dexmedetomidine and lorazepam sedation in 106 mechanically ventilated patients (three patients were withdrawn).[@CR17] Sedation with dexmedetomidine resulted in more days thriving without delirium or coma, a lower prevalence of coma, and more on-target sedation than lorazepam administration.[@CR17] The follow-up Safety and Efficacy of Dexmedetomidine Compared with Midazolam (SEDCOM) trial randomized 375 patients to dexmedetomidine or midazolam sedation.[@CR18] Though no difference in time at target sedation was observed, patients sedated with dexmedetomidine had a reduced prevalence of delirium with a reduced duration of mechanical ventilation.[@CR18]

While we did not randomize patients according to whether they were septic on admission to our MENDS RCT,[@CR17] we had decided *a priori* to perform a *post-hoc* analysis of septic *vs* non-septic subgroups of patients who received dexmedetomidine-based or lorazepam-based sedation for up to five days.[@CR49] More than half of the 103 patients included (63 patients; 31 dexmedetomidine, 32 lorazepam) were admitted with sepsis. Demographic and severity data were balanced between the two cohorts. Compared with septic patients who received lorazepam, the septic patients who received dexmedetomidine had 3.2 more delirium/coma-free days and more ventilator-free days on average (95% confidence intervals for difference, 1.1-4.9 and 0.3-11.1, respectively) (Fig. [2](#Fig2){ref-type="fig"}). The risk of dying at 28 days was reduced by 70% (hazard ratio 0.3: 0.1-0.9) in dexmedetomidine patients with sepsis compared with the lorazepam patients (Fig. [3](#Fig3){ref-type="fig"}). In addition to alternate effects on innate immunity and physiological response to the infection,[@CR49],[@CR50] we speculate that the immune dysfunctional effects of sleep deprivation in the lorazepam group may have contributed to the higher death rate from infection. Our speculation is supported by data from the SEDCOM trial in which the rate of infection was 50% lower in the DEX group.[@CR18] Fig. 2Days free from complications associated with acute brain failure in septic intensive care unit patients sedated with the α~2~ adrenoceptor agonist, dexmedetomidine, or the benzodiazepine, lorazepam. Data are represented in a box and whisker plot reflecting the median, lower, and upper quartiles and the lower and upper extremes of days/patient. Reproduced with permission from Pandharipande *et al.* [@CR49] Fig. 3Kaplan-Meier curve showing the probability of survival according to sedation group during the first 28 days following admission to the intensive care unit for sepsis. Avoidance of lorazepam sedation using dexmedetomidine decreased the probability of dying within 28 days by 70%. Reproduced with permission from Pandharipande *et al.* [@CR49]

Functional MRI was performed in volunteers tested on three separate occasions during which they received saline, dexmedetomidine, or midazolam.[@CR40] Subjects were infused to achieve a target concentration that produced equivalent sedation, as assessed by electroencephalography (bispectral index \[BIS\]) and observer rating (Observer Assessment of Alertness/Sedation \[OAA/S\]). In a single subject, sleep occurred during saline infusion while undergoing fMRI. Subtraction scans were performed to yield the difference in blood oxygen level-dependent (BOLD) activity between natural sleep and the sedated states provided by either dexmedetomidine or midazolam. There were fewer voxels of BOLD activity seen in the subtraction scan between dexmedetomidine-sedation and natural sleep (Fig. [4](#Fig4){ref-type="fig"}a) than between midazolam-sedation and natural sleep (Fig. [4](#Fig4){ref-type="fig"}b).Fig. 4Sedation with α~2~ adrenoceptor agonist produces a more "natural sleep" response than sedation with benzodiazepine. Functional magnetic resonance imaging (fMRI) was performed in volunteers tested on three separate occasions, during which they received saline, dexmedetomidine, or midazolam.[@CR40] Subjects were infused to achieve a target concentration that produced equivalent sedation as assessed by electroencephalography (bispectral index, BIS) and observer rating (Observer Assessment of Alertness/Sedation, OAA/S). In a single subject, sleep occurred during saline infusion while undergoing fMRI. Subtraction scans were performed yielding the difference in blood oxygen level-dependent (BOLD) activity between natural sleep and the sedated states provided by either dexmedetomidine or midazolam. There were fewer voxels of BOLD activity seen in the subtraction scan between dexmedetomidine-sedation and natural sleep (**a**) than seen between midazolam-sedation and natural sleep (**b**)

The changes in neuronal activity that benzodiazepines induce are inconsistent with the deeper stages of NREM sleep. Consequently, the restorative properties of natural sleep are lacking in patients on prolonged benzodiazepine infusions, resulting in acute brain and immune system dysfunction that may complicate the recovery of critically ill patients. The addictive properties of benzodiazepines result in a rapid escalation in dose requirements. When benzodiazepines are part of the sedative regimen, it is difficult to perform "interruption of sedation" standard of nursing care because of the likelihood of the supervention of withdrawal phenomena, including a hypernoradrenergic state and anxiogenesis.

Conclusions {#Sec5}
===========

Sedative-hypnotic agents contribute to the development of delirium in critically ill patients.[@CR17]-[@CR19] We hypothesize that α~2~ adrenoceptor agonists are beneficial relative to benzodiazepines due to subtle differences in their mechanisms of action. In particular, we suggest that dexmedetomidine sedation may provide a more restorative -- perhaps "natural sleep-like" - state than GABAergic sedatives, such as the benzodiazepines. Our proposition centres on the discovery that α~2~ adrenoceptor agonists act on the sleep pathway at the brainstem level, while GABAergic agents act at the level of the hypothalamus. The dissimilar actions produce different sedative profiles for the two classes of agents, and we suspect they contribute to the risk of delirium in the intensive care unit through alternate effects on the restorative nature of the sedation. This may also explain why outcomes from sepsis[@CR49] and infection[@CR18] are very different for α~2~ adrenoceptor agonists than they are for GABAergic agents (though we suspect ongoing studies will identify the importance of the immune actions of the two drug classes). Furthermore, α~2~ adrenoceptor agonists may provide a state from which patients are rousable, possibly through preserved orexinergic signalling. Rousability is important to facilitate weaning from mechanical ventilation and neurological examination. Finally, in addition to preventing the cognitive consequences of sleep deprivation, the drugs alternately affect memory formation. We suggest that the impairment of memory formation by GABAergic drugs contributes to the acute confusion in delirium, while α~2~ adrenoceptor agonists produce little in the way of memory impairment and thus reduce the burden of patient disorientation.

Clinical studies continue to reveal the benefits of understanding the differences in sedative-hypnotic mechanisms, and as further mechanistic understanding can drive advances in clinical medicine, we urge clinicians and scientists alike to continue this fruitful path of discovery to aid patient care at the bedside. The adoption of "sedation holidays"[@CR51] and "spontaneous breathing trials"[@CR52] have shown that sedation in our most vulnerable patients is an important determinant of outcome. We now have the opportunity to define the agents for best sedating our patients, and we suggest that α~2~ adrenoceptor agonists may offer particular advantages in the critically ill.[@CR17],[@CR18],[@CR49],[@CR50]
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